What e-therapeutics PLC does

e-therapeutics PLC operates under the trade name Tangram Therapeutics and is a for-profit biotechnology company developing RNAi-based medicines. Its functional focus is nucleic-acid therapeutics — leveraging RNA interference as the mechanism of action — which positions it within a specialized subset of the broader gene-silencing drug class. The company is headquartered in the City of London, United Kingdom, suggesting a UK-based R&D and corporate footprint, though no office network, subsidiary structure, or international presence was disclosed in the source.

The company's distinguishing technical layer is computational drug discovery applied to RNAi target identification, sequence design, and likely optimization of oligonucleotide chemistry and delivery characteristics. This implies an in silico platform — encompassing genomics data processing, target prioritization, and possibly proprietary modeling — that sits upstream of wet-lab validation. The source material does not specify named pipeline candidates, target indications, development stages, partnership vehicles, or platform architecture in detail, and the firm's public website at etherapeutics.co.uk resolved only to a loader page with no substantive product information. As a result, the precise scope of the pipeline, modality-specific chemistry capabilities, and any delivery-platform IP cannot be characterized from the available data.

No revenue mechanics, pricing model, customer agreements, licensing arrangements, or capital-raise history were disclosed in the source. The IPO status field in the firmographic data records the company as "private," though the use of "PLC" in the legal name traditionally denotes a UK public limited company structure; this inconsistency in the source data is noted but not resolved. No management team, board composition, headcount, funding rounds, or strategic transactions were disclosed. The company therefore should be treated as an opaque, early-profile biotech with disclosed positioning but limited verifiable operational detail.

Name

e-therapeutics PLC

Website

https://etherapeutics.co.uk

Company type

Private

Short description

e-therapeutics PLC, operating as Tangram Therapeutics, is a UK-based biotech developing RNAi-based medicines using computational drug discovery to identify and advance nucleic-acid therapeutic candidates.

Ownership category

akta.pro rank

Product category

RNAi Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNAi therapeutics
• Computational drug discovery
• Biotech medicines
• In silico drug discovery
• RNA interference therapeutics

Headquarters

HQ city

City Of London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

e-therapeutics plc operates as Tangram Therapeutics, a biotech company that develops RNAi-based medicines using computational drug discovery. The company combines RNA interference biology with in silico discovery methods to identify and advance therapeutic candidates for downstream development.

Product overview

No substantive product information available from the source. The source content shows only a loading/verification page with no details about the company's offerings, products, or services.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Expansion highlights2 records

Direct peers

• Alnylam Pharmaceuticals: The leading RNAi therapeutics company with multiple approved siRNA-based medicines. Directly comparable as it operates in the same RNAi drug discovery and development space serving similar patient populations and partners.
• Dicerna Pharmaceuticals: Acquired by Novo Nordisk, Dicerna developed GalXC RNAi platform for liver and extrahepatic targets. Highly comparable RNAi platform company that demonstrates the partnership/M&A pathway for smaller RNAi platform players.
• Wave Life Sciences: Clinical-stage RNA medicines company using stereopure oligonucleotide chemistry across RNAi and antisense modalities. Directly comparable as a platform-driven RNA therapeutics developer with overlapping delivery and target-selection challenges.
• Silence Therapeutics: UK-listed RNAi therapeutics company developing siRNA-based medicines, often via partnerships with larger pharma. Directly comparable as a London-based peer pursuing the same RNAi modality with a similar scale profile.
• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs and a deep pipeline. Closely related peer operating in adjacent RNA-targeted modalities targeting similar indications.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with a broad pipeline across multiple disease areas using proprietary delivery platforms. Directly comparable in modality (siRNA), target disease areas, and platform-driven discovery approach.

Broad incumbents

• Dicerna Pharmaceuticals (Novo Nordisk subsidiary): Now operating within Novo Nordisk's R&D organization, Dicerna's RNAi platform serves cardiometabolic and rare disease pipelines. Comparable as a large-incumbent channel that absorbs smaller RNAi platforms via acquisition.
• Moderna: Large mRNA therapeutics company with broad pipeline across vaccines, oncology, and rare diseases. Comparable as a broader RNA-medicine incumbent using computational biology for RNA design and target selection.
• Genevant Sciences: Lipid nanoparticle (LNP) delivery technology company enabling RNA-based therapeutics including siRNA. Comparable as a delivery-focused enabler in the broader RNAi/RNA therapeutics ecosystem.

Emerging players

• Aro Biotherapeutics: Clinical-stage biotech developing tissue-targeted siRNA and other oligonucleotide therapeutics using Centyrin-based delivery. Emerging peer with overlapping RNAi approach but differentiated delivery technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/TangramTx
• LinkedInlinkedin.com/company/tangram-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about e-therapeutics PLC